^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Excerpt:
...Group A: KIF5B/RET or related variant RET fusions....
Trial ID:
Evidence Level:
Resistant: C4 – Case Studies
Title:

P08.01: Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors

Published date:
02/19/2021
Excerpt:
We present here a case of TKI resistance in a patient with KIF5B-RET fusion advanced NSCLC. Following progression on cabozantinib, he was started on selpercatinib. At the time of initial diagnosis molecular profiling revealed a KIF5B-RET fusion...he initiated cabozantinib, remained on therapy for 4 months with subsequent progression at multiple sites. He was treated with selpercatinib for 23 months before oligometastatic progression. Molecular analysis via cell-free DNA again revealed KIF5B-RET fusion without any alterations known to cause TKI resistance.